NASDAQ:PRPO Precipio Q2 2024 Earnings Report $6.03 -0.70 (-10.40%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$6.14 +0.11 (+1.82%) As of 04/25/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History Precipio EPS ResultsActual EPS-$0.83Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APrecipio Revenue ResultsActual Revenue$4.44 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrecipio Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call DateMonday, August 19, 2024Conference Call Time5:00PM ETUpcoming EarningsPrecipio's next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules. Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Earnings HistoryCompany ProfilePowered by Precipio Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 19, 2024 ShareLink copied to clipboard.There are 2 speakers on the call. Operator00:00:00to the Precipio Second Quarter 20 24 Shareholder Update Conference Call. All participants will be in a listen only mode. Please note that the conference is being recorded. Statements made during this call contain forward looking statements about our business. You should not place undue reliance on forward looking statements as these statements are based upon our current expectations, forecasts and assumptions and are subject to significant risks and uncertainties. Operator00:00:33These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risk and uncertainties that could cause our actual results to differ materially from those set forth in any forward looking statements include, but are not limited to, the matters listed under Risk Factors in our annual report on Form 10 ks for the year ended December 31, 2023, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward looking statements, speak only to the date they are provided unless an earlier date is indicated. We do not undertake any obligation to publicly update any statements or information, including forward looking statements, whether as a result of new information, future events or otherwise, except as required by law. Operator00:01:49Now, let me turn the floor over to Piyuan Daniele, Precipio's CEO. Please go ahead. Speaker 100:01:58Thank you very much. Good afternoon, everyone, and thank you for joining our 2024 Q2 shareholder update call. I'd like to thank those of you who submitted questions. As always, I will try my best to address them during this call. As you saw in our recent 10 Q filing last week, we are on track to hit our goals for this year. Speaker 100:02:17Revenue continued to grow with the pathology division reaching breakeven at the end of Q2. I'm pleased to inform that so far we've continued on that track and in Q3 to date we are exceeding our breakeven target for the pathology division. We have a solid team, our existing customer base is stable and our new customer base is growing. We will continue to build an excess cushion of revenue to ensure that the pathology division fulfills its purpose within the company's strategy, which is to serve as a cost neutral rapid R and D facility to develop our products, while itself remaining profitable and generating cash for the company. In the Products division, we also continue to make progress towards breakeven. Speaker 100:03:00In the past, we discussed 3 large customers that we are working with to go live with our Heat Stream program and when they do, this division will reach its target. Once we reach breakeven for this division, the entire company will be profitable. In this quarter, 2 of the 3 customers have gone live and are growing their volume and adding panels. We expect that by the end of this quarter they will be in full fledged activity which means that going into Q4, we can expect that these customers will contribute to an increase in revenue. The 3rd customer is still in progress and is working through several operational issues before they go live. Speaker 100:03:36We are working diligently with them in order to ensure that this third customer will also be fully on boarded too. Of course, we have quite a few other small and midsize customers that are either in the process or have gone live during Q2 and we're starting to see their orders come in. Each of these customers forms yet another building block of recurring revenue to the company and brings us closer to hitting our breakeven targets. In the previous shareholder call, I commented on our work with the distributors to revamp the working relationship with them and identify the recipe for success. We work closely with the management teams of our distributors to formulate a plan and in Q2, we began to put it in place. Speaker 100:04:17We began to see the fruits of the new recipe with our distributors in the form of better customer targeting, more introductions to conversations with the right decision makers and progress towards bringing those customers on board. Some of you have asked why are we spending time and effort with distributors when so far we've been more successful with our direct sales approach. The reason is we believe that distributors are the key to scaling up the business. Although for now we're focused on reaching profitability, the total market just for the HemeScreen product is approximately $400,000,000 annually in the U. S. Speaker 100:04:53And a similar amount worldwide. We are not even at 1% of that market share and the way to scale up is through our distributors. Our U. S. Distributors, Hard Knoll Health, Thermo Fisher and McKesson collectively employ hundreds of sales reps that have spent years building relationships with customers. Speaker 100:05:11They know who the decision makers are within those customers and what is the process and best approach to sell product into them. And most importantly, they have access to these customers. It's no secret that in the healthcare field, leveraging a distribution network has the potential for business to scale up far more efficiently and rapidly by tapping into those established channels, expertise and resources and enabling faster market penetration and broader reach as opposed to attempting to go only direct. Therefore, as we establish our presence in the market and build our customer base, we believe that the way to scale up this business and capture significant market share is through our distribution channel. But like with any other partner you work with, it takes time to build successful relationships. Speaker 100:05:58We continue to work closely with our distributors to refine the program and messaging and to build relationships to help foster growth in our sales. Next, I'd like to discuss our cash position. As you saw in Q2, we actually had an increase in cash of approximately $300,000 While this is terrific news and yes, we are getting close, this is not to be confused with us being profitable just yet. We're still dealing with the aftermath issues from the Change Healthcare hack earlier this year, including fund transfers from Change Healthcare, delayed payments to Medicare and other payers, and we've not yet returned to a steady state of billing collection. However, we believe that the situation is getting much better and we are moving towards returning to that stable situation we had prior to the half. Speaker 100:06:50From an operational perspective, we are reducing our cash burn and moving towards breakeven. And as we stand today, we believe that we have sufficient cash to meet our obligations and reach that target of profitability by year end. You've heard me say this many times, it's time for our company to be financially independent and stand on our own 2 feet. I still believe that we have sufficient resources to reach that point. Next, I'd like to provide an update on our process with the FDA. Speaker 100:07:19We submitted to the FDA the required materials for our pre submission meeting. Those materials have been accepted and the meeting with the FDA has been scheduled for later this year. We feel that we are in a good position to submit our application to the FDA soon after the meeting and we hope to receive approval sometime in 2025. We're still seeing in the market significant confusion around the FDA ruling, both from customers who are not sure how to handle the situation and from manufacturers who have not yet decided what they're going to do. We actually view this as a competitive advantage for us and believe that this ruling will weed out quite a few of the competitors. Speaker 100:07:57Once received, we believe having an FDA seal of approval on our products will help us gain further market share and provide additional credibility to our products. Finally, I'd like to comment on our share price performance. For the recent months, we've been hovering around the $5 to $6 range and it seems that the share price is at least stable and no longer suffers from the tremendous shorting pressures we used to experience. So that's a good thing. Having said that, if you take our Q2 revenues of $4,400,000 which translates into about $17,500,000 annualized run rate, this still equates to a market cap of less than 0.5 times on revenue multiple. Speaker 100:08:39Looking at comparables in the market and at the company's situation, this doesn't seem to us and to many outside observers as a reasonable multiple. But we ask ourselves what's keeping the stock price at its current place. We consider 2 factors. The first is that the market is still skeptical of our performance, our revenue growth and our cash needs and believes we will still need to raise diluted capital. As we continue on track, the next couple of quarters will hopefully dissolve this notion entirely. Speaker 100:09:09The second factor is that the company and me personally have not spent any significant time and resources on the IR side of the Investor Relations. All companies and especially MicroCap companies such as ours battle for investor attention and work to build their presence and brand within the investment community. For the past few years, we've spent our effort building our business and have spent very little time on the IR side. Our plan is that upon achieving our goals by the end of this year and demonstrating to the market that we are indeed a profitable company with a growing customer base with a backlog and pipeline of new business and a roadmap to scale this business to our distributors, then we have a story that we can go out and share with the investor community. A combination of presence and investor conferences and meetings coupled with work on the digital side can help build a substantial audience of people who will potentially follow the company. Speaker 100:10:05With continuous performance and results, that should translate into an increase in trading volume and presumably a correction of our company's revenue multiple for its current 0.5 times revenue to a number that is more in line with industry comparable. Needless to say, our company is working hard to achieve its business results and the impact of the business results on the company's share price is a key focal point at all times. In summary, we're in a good place and I'm really excited to continue with the momentum we have. With the pathology division stabilized and exceeding its breakeven target and product division heading in that direction, we have enough gas in the tank to get there. I think the hard work will pay off when our company reaches its goals for 2024. Speaker 100:10:51Furthermore, as you can see, we're also thinking about our strategy for 2025 in terms of scaling up the products business as well as rekindling our IR strategy so that we can translate all the good work that our team has accomplished into shareholder value. I'd like to thank you for your support and I look forward to connecting with you on our next quarterly call. Thank you and have a nice evening. Operator00:11:17Ladies and gentlemen, the conference has now concluded. We do thank you for attending today's presentation. You may now disconnect your lines.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallPrecipio Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K) Precipio Earnings HeadlinesPrecipio trading halted, volatility trading pauseApril 24 at 11:59 PM | markets.businessinsider.comEarnings call transcript: Precipio Q4 2024 sees revenue growth, strategic shiftsApril 2, 2025 | investing.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIElon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.April 26, 2025 | Brownstone Research (Ad)Precipio Inc (PRPO) Q4 2024 Earnings Call Highlights: Break-Even Achieved and Strategic Growth ...April 2, 2025 | finance.yahoo.comPrecipio, Inc. (NASDAQ:PRPO) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comPrecipio Reports Positive Q4 Financial ResultsApril 1, 2025 | tipranks.comSee More Precipio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email. Email Address About PrecipioPrecipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.View Precipio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 2 speakers on the call. Operator00:00:00to the Precipio Second Quarter 20 24 Shareholder Update Conference Call. All participants will be in a listen only mode. Please note that the conference is being recorded. Statements made during this call contain forward looking statements about our business. You should not place undue reliance on forward looking statements as these statements are based upon our current expectations, forecasts and assumptions and are subject to significant risks and uncertainties. Operator00:00:33These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risk and uncertainties that could cause our actual results to differ materially from those set forth in any forward looking statements include, but are not limited to, the matters listed under Risk Factors in our annual report on Form 10 ks for the year ended December 31, 2023, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward looking statements, speak only to the date they are provided unless an earlier date is indicated. We do not undertake any obligation to publicly update any statements or information, including forward looking statements, whether as a result of new information, future events or otherwise, except as required by law. Operator00:01:49Now, let me turn the floor over to Piyuan Daniele, Precipio's CEO. Please go ahead. Speaker 100:01:58Thank you very much. Good afternoon, everyone, and thank you for joining our 2024 Q2 shareholder update call. I'd like to thank those of you who submitted questions. As always, I will try my best to address them during this call. As you saw in our recent 10 Q filing last week, we are on track to hit our goals for this year. Speaker 100:02:17Revenue continued to grow with the pathology division reaching breakeven at the end of Q2. I'm pleased to inform that so far we've continued on that track and in Q3 to date we are exceeding our breakeven target for the pathology division. We have a solid team, our existing customer base is stable and our new customer base is growing. We will continue to build an excess cushion of revenue to ensure that the pathology division fulfills its purpose within the company's strategy, which is to serve as a cost neutral rapid R and D facility to develop our products, while itself remaining profitable and generating cash for the company. In the Products division, we also continue to make progress towards breakeven. Speaker 100:03:00In the past, we discussed 3 large customers that we are working with to go live with our Heat Stream program and when they do, this division will reach its target. Once we reach breakeven for this division, the entire company will be profitable. In this quarter, 2 of the 3 customers have gone live and are growing their volume and adding panels. We expect that by the end of this quarter they will be in full fledged activity which means that going into Q4, we can expect that these customers will contribute to an increase in revenue. The 3rd customer is still in progress and is working through several operational issues before they go live. Speaker 100:03:36We are working diligently with them in order to ensure that this third customer will also be fully on boarded too. Of course, we have quite a few other small and midsize customers that are either in the process or have gone live during Q2 and we're starting to see their orders come in. Each of these customers forms yet another building block of recurring revenue to the company and brings us closer to hitting our breakeven targets. In the previous shareholder call, I commented on our work with the distributors to revamp the working relationship with them and identify the recipe for success. We work closely with the management teams of our distributors to formulate a plan and in Q2, we began to put it in place. Speaker 100:04:17We began to see the fruits of the new recipe with our distributors in the form of better customer targeting, more introductions to conversations with the right decision makers and progress towards bringing those customers on board. Some of you have asked why are we spending time and effort with distributors when so far we've been more successful with our direct sales approach. The reason is we believe that distributors are the key to scaling up the business. Although for now we're focused on reaching profitability, the total market just for the HemeScreen product is approximately $400,000,000 annually in the U. S. Speaker 100:04:53And a similar amount worldwide. We are not even at 1% of that market share and the way to scale up is through our distributors. Our U. S. Distributors, Hard Knoll Health, Thermo Fisher and McKesson collectively employ hundreds of sales reps that have spent years building relationships with customers. Speaker 100:05:11They know who the decision makers are within those customers and what is the process and best approach to sell product into them. And most importantly, they have access to these customers. It's no secret that in the healthcare field, leveraging a distribution network has the potential for business to scale up far more efficiently and rapidly by tapping into those established channels, expertise and resources and enabling faster market penetration and broader reach as opposed to attempting to go only direct. Therefore, as we establish our presence in the market and build our customer base, we believe that the way to scale up this business and capture significant market share is through our distribution channel. But like with any other partner you work with, it takes time to build successful relationships. Speaker 100:05:58We continue to work closely with our distributors to refine the program and messaging and to build relationships to help foster growth in our sales. Next, I'd like to discuss our cash position. As you saw in Q2, we actually had an increase in cash of approximately $300,000 While this is terrific news and yes, we are getting close, this is not to be confused with us being profitable just yet. We're still dealing with the aftermath issues from the Change Healthcare hack earlier this year, including fund transfers from Change Healthcare, delayed payments to Medicare and other payers, and we've not yet returned to a steady state of billing collection. However, we believe that the situation is getting much better and we are moving towards returning to that stable situation we had prior to the half. Speaker 100:06:50From an operational perspective, we are reducing our cash burn and moving towards breakeven. And as we stand today, we believe that we have sufficient cash to meet our obligations and reach that target of profitability by year end. You've heard me say this many times, it's time for our company to be financially independent and stand on our own 2 feet. I still believe that we have sufficient resources to reach that point. Next, I'd like to provide an update on our process with the FDA. Speaker 100:07:19We submitted to the FDA the required materials for our pre submission meeting. Those materials have been accepted and the meeting with the FDA has been scheduled for later this year. We feel that we are in a good position to submit our application to the FDA soon after the meeting and we hope to receive approval sometime in 2025. We're still seeing in the market significant confusion around the FDA ruling, both from customers who are not sure how to handle the situation and from manufacturers who have not yet decided what they're going to do. We actually view this as a competitive advantage for us and believe that this ruling will weed out quite a few of the competitors. Speaker 100:07:57Once received, we believe having an FDA seal of approval on our products will help us gain further market share and provide additional credibility to our products. Finally, I'd like to comment on our share price performance. For the recent months, we've been hovering around the $5 to $6 range and it seems that the share price is at least stable and no longer suffers from the tremendous shorting pressures we used to experience. So that's a good thing. Having said that, if you take our Q2 revenues of $4,400,000 which translates into about $17,500,000 annualized run rate, this still equates to a market cap of less than 0.5 times on revenue multiple. Speaker 100:08:39Looking at comparables in the market and at the company's situation, this doesn't seem to us and to many outside observers as a reasonable multiple. But we ask ourselves what's keeping the stock price at its current place. We consider 2 factors. The first is that the market is still skeptical of our performance, our revenue growth and our cash needs and believes we will still need to raise diluted capital. As we continue on track, the next couple of quarters will hopefully dissolve this notion entirely. Speaker 100:09:09The second factor is that the company and me personally have not spent any significant time and resources on the IR side of the Investor Relations. All companies and especially MicroCap companies such as ours battle for investor attention and work to build their presence and brand within the investment community. For the past few years, we've spent our effort building our business and have spent very little time on the IR side. Our plan is that upon achieving our goals by the end of this year and demonstrating to the market that we are indeed a profitable company with a growing customer base with a backlog and pipeline of new business and a roadmap to scale this business to our distributors, then we have a story that we can go out and share with the investor community. A combination of presence and investor conferences and meetings coupled with work on the digital side can help build a substantial audience of people who will potentially follow the company. Speaker 100:10:05With continuous performance and results, that should translate into an increase in trading volume and presumably a correction of our company's revenue multiple for its current 0.5 times revenue to a number that is more in line with industry comparable. Needless to say, our company is working hard to achieve its business results and the impact of the business results on the company's share price is a key focal point at all times. In summary, we're in a good place and I'm really excited to continue with the momentum we have. With the pathology division stabilized and exceeding its breakeven target and product division heading in that direction, we have enough gas in the tank to get there. I think the hard work will pay off when our company reaches its goals for 2024. Speaker 100:10:51Furthermore, as you can see, we're also thinking about our strategy for 2025 in terms of scaling up the products business as well as rekindling our IR strategy so that we can translate all the good work that our team has accomplished into shareholder value. I'd like to thank you for your support and I look forward to connecting with you on our next quarterly call. Thank you and have a nice evening. Operator00:11:17Ladies and gentlemen, the conference has now concluded. We do thank you for attending today's presentation. You may now disconnect your lines.Read morePowered by